A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations
Category & Conditions: Cancer
Medicine: Lorbrena (lorlatinib)
ClinicalTrials.gov Identifier (NCT): NCT01970865
Protocol ID: B7461001
PrintDownloadOpen Plain Language Summary Result: Click here